Monoclonal

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
OBJECTIVE: To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active …
Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan Nordström, Michael Nurmohamed, Bjorn Gudbjornsson, Jon Lampa, Kim Hørslev-Petersen, Till Uhlig, Gerdur Grondal, Mikkel Østergaard, Marte S. Heiberg, Jos Twisk, Kristina Lend, Simon Krabbe, Lise Hejl Hyldstrup, Joakim Lindqvist, Anna-Karin Hultgård Ekwall, Kathrine Lederballe Grøn, Meliha Kapetanovic, Francesca Faustini, Riitta Tuompo, Tove Lorenzen, Giovanni Cagnotto, Eva Baecklund, Oliver Hendricks, Daisy Vedder, Tuulikki Sokka-Isler, Tomas Husmark, Maud-Kristine Aga Ljoså, Eli Brodin, Torkell Ellingsen, Annika Söderbergh, Milad Rizk, Åsa Reckner Olsson, Per Larsson, Line Uhrenholt, Søren Andreas Just, David John Stevens, Trine Bay Laurberg, Gunnstein Bakland, Inge C. Olsen, Ronald van Vollenhoven, NORD-STAR study group
Cite DOI
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is …
Kristin K. Jørgensen, Guro L. Goll, Joe Sexton, Nils Bolstad, Inge C. Olsen, Øivind Asak, Ingrid P. Berset, Ingrid M. Blomgren, Katrine Dvergsnes, Jon Florholmen, Svein O. Frigstad, Magne Henriksen, Jon Hagfors, Gert Huppertz-Hauss, Espen A. Haavardsholm, Rolf A. Klaasen, Bjørn Moum, Geir Noraberg, Ulf Prestegård, Jan H. Rydning, Liv Sagatun, Kathrine A. Seeberg, Roald Torp, Cecilia Vold, David J. Warren, Carl M. Ystrøm, Knut E. A. Lundin, Tore Kvien, Jørgen Jahnsen
Cite DOI
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that …
G. L. Goll, K. K. Jørgensen, J. Sexton, I. C. Olsen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, K. S. Tveit, M. Lorentzen, I. P. Berset, B. T. S. Fevang, S. Kalstad, K. Ryggen, D. J. Warren, R. A. Klaasen, Ø Asak, S. Baigh, I. M. Blomgren, Ø Brenna, T. J. Bruun, K. Dvergsnes, S. O. Frigstad, I. M. Hansen, I. S. H. Hatten, G. Huppertz-Hauss, M. Henriksen, S. S. Hoie, J. Krogh, I. P. Midtgard, P. Mielnik, B. Moum, G. Noraberg, A. Poyan, U. Prestegård, H. U. Rashid, E. K. Strand, K. Skjetne, K. A. Seeberg, R. Torp, C. M. Ystrøm, C. Vold, C. C. Zettel, K. Waksvik, B. Gulbrandsen, J. Hagfors, C. Mørk, J. Jahnsen, T. K. Kvien
Cite DOI
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Kristin K. Jørgensen, Knut E. Lundin, Inge C. Olsen, Tore K. Kvien, Jørgen Jahnsen
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI